immunoprecise.com (IPA) - Company Sales

The resilience of ImmunoPrecise Antibodies (IPA) is based on a network of laboratories in the US, Canada, and Europe. Actual company sales on GURU.Markets highlight this growth trend, where the value of 0.02 serves as the current indicator. Stable margins are maintained through the optimization of equipment costs, while the implementation of virtual testing minimizes hazardous waste, confirming a commitment to environmental principles.

ImmunoPrecise Antibodies Ltd. (IPA) Company Revenue: for the period 07/04/2022 - 09/04/2025

Analytical breakdowns for ImmunoPrecise Antibodies Ltd (IPA)

- market price and analyst price targets:

Market Price ImmunoPrecise|IPA - Analyst Consensus Forecast

- market capitalization indicators:

Market Valuation ImmunoPrecise Antibodies Ltd.|IPA - Enterprise Value

- balance sheet equity data:

Net Assets per Share ImmunoPrecise Antibodies|IPA - Company Book Value|Market Capitalization to Book Value immunoprecise.com|IPA - Company Total Assets

- debt and solvency information:

Debt to Capital ImmunoPrecise Antibodies|IPA - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital ImmunoPrecise|IPA - Company Aggregate Debts|Debts to Book Capitalization ImmunoPrecise Antibodies Ltd.|IPA - Company Long-Term Debt|Company Short-Term Indebtedness ImmunoPrecise Antibodies|Intermediate Liquidity Ratio immunoprecise.com

- earnings and market multiples details:

IPA - Net Profit|Company Profit Forecast ImmunoPrecise Antibodies|IPA - P/E Multiple|Future Price to Earnings ImmunoPrecise|IPA - Price/Earnings to Growth Ratio|Company Value to EBITDA ImmunoPrecise Antibodies Ltd.|IPA - Operating profit EBITDA|Earnings per share for the last 12 months ImmunoPrecise Antibodies|IPA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months immunoprecise.com|IPA - Earnings growth in current year|Expected net earnings per share growth next year ImmunoPrecise Antibodies

- sales volume and revenue indicators:

IPA - Company Revenue|Company Future Sales ImmunoPrecise|IPA - P/S Multiple|Market Cap to Expected Sales Ratio ImmunoPrecise Antibodies Ltd.

Summary company analysis:IPA, immunoprecise.com

Original product of ImmunoPrecise Antibodies

This indicator captures actual daily cash inflows, enabling the identification of systemic business degradation or expansion through the analysis of real cash flows without time lags. By tracking the company's product sales volumes, investors can assess the monetization of the LENS ai AI engine and the delivery speed of therapeutic antibodies to Big Pharma, confirming the market demand for the technological advantage of ImmunoPrecise Antibodies (IPA).

Analysis of competing companies